RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 70 filers reported holding RUBIUS THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $29 | -100.0% | 169,571 | -24.6% | 0.00% | – |
| Q3 2022 | $98,000 | -87.4% | 224,764 | -75.4% | 0.00% | – |
| Q2 2022 | $777,000 | -85.6% | 912,957 | -7.0% | 0.00% | -100.0% |
| Q1 2022 | $5,407,000 | +964.4% | 981,476 | +1771.3% | 0.00% | – |
| Q4 2021 | $508,000 | +41.1% | 52,449 | +160.4% | 0.00% | – |
| Q3 2021 | $360,000 | -85.9% | 20,138 | -80.8% | 0.00% | -100.0% |
| Q2 2021 | $2,560,000 | +798.2% | 104,893 | +876.7% | 0.00% | – |
| Q1 2021 | $285,000 | -8.4% | 10,739 | -73.8% | 0.00% | – |
| Q4 2020 | $311,000 | -15.0% | 40,979 | -44.0% | 0.00% | – |
| Q3 2020 | $366,000 | +351.9% | 73,143 | +302.9% | 0.00% | – |
| Q1 2020 | $81,000 | -96.5% | 18,155 | -92.6% | 0.00% | -100.0% |
| Q4 2019 | $2,324,000 | +395.5% | 244,655 | +309.0% | 0.00% | +200.0% |
| Q3 2019 | $469,000 | -67.2% | 59,819 | -34.1% | 0.00% | -50.0% |
| Q2 2019 | $1,428,000 | – | 90,803 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARCH Venture Management, LLC | 2,618,351 | $20,554,000 | 22.50% |
| Flagship Pioneering Inc. | 38,296,526 | $300,628,000 | 16.44% |
| HARBOURVEST PARTNERS LLC | 986,878 | $7,747,000 | 3.22% |
| Artal Group S.A. | 2,833,791 | $22,246,000 | 0.89% |
| EcoR1 Capital, LLC | 260,152 | $2,042,000 | 0.26% |
| Cormorant Asset Management, LP | 491,700 | $3,860,000 | 0.24% |
| Nikko Asset Management Americas, Inc. | 1,456,842 | $11,436,000 | 0.20% |
| ARK Investment Management | 730,890 | $5,737,000 | 0.12% |
| Leap Investments LP | 16,300 | $128,000 | 0.06% |
| Baillie Gifford | 4,240,767 | $33,290,000 | 0.04% |